The main expected result of a vaccine against viruses is the ability to produce neutralizing antibodies. Currently, several vaccines against SARS-CoV-2 are being applied to prevent mortal complications, being Pfizer-BioNTech (BNT162b2) one of the first to be authorized in the USA and Mexico (11 December 2020). This study evaluated the efficacy of this vaccine on antibody production with neutralizing capacity and its side effects in healthcare workers with and without prior SARS-CoV-2 infection and in a group of unvaccinated individuals with prior COVID-19. The main findings are the production of 100% neutralizing antibodies in both groups after the second dose, well-tolerated adverse effects, the possible presence of immunosenescence, and finally, we support that a single dose of this vaccine in individuals with prior COVID-19 would be sufficient to achieve an immunization comparable to people without prior COVID-19 with a complete vaccination program (2 doses).
Background: It has recently been argued that asthma does not increase the risk of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. If so, the prevalence of asthma in subjects diagnosed with COVID-19 should be lower than in the general population.
Objective: To determine the prevalence of asthma in Mexican children and adults with SARS-CoV-2 infection.Methods: A public database of the Epidemiological Surveillance System for Viral Respiratory Disease in Mexico was analyzed. Those who underwent the real-time reverse transcriptase-polymerase chain reaction-SARS-CoV-2 (rtRT-PCR-SARS-CoV-2) test from February 27 to June 21, 2020, were included. In addition to the prevalence of asthma, some factors associated with it were investigated.
Results: Data from 417,366 subjects were analyzed. Asthma prevalence in children, adults, and global were 3.7%, 3.3%, and 3.3%, respectively. Although the asthma prevalence was lower in SARS-CoV-2 positive over negative patients, significant differences were only found in adults (2.8% vs. 3.7% respectively; odds ratio (OR) = 0.74; 95% confidence interval (CI): 0.71–0.77); but not in children (3.5% vs. 3.8%, respectively; OR = 0.91; 95%CI: 0.76–1.10). Multivariate analysis showed in younger than 18 years that girls and immunosuppression were factors associated with a decrease in the odds to develop asthma. In adults, asthma was positively associated with females, obesity, smoking, immunosuppression, chronic obstructive pulmonary disease, arterial hypertension, and cardiovascular disease.
Antecedentes: En México son escasos los estudios encaminados a establecer la prevalencia de la rinitis alérgica y la dermatitis atópica en adolescentes tardíos.Objetivo: Determinar la prevalencia de rinitis alérgica y dermatitis atópica en adolescentes tardíos y compararla conforme el sexo.Métodos: Estudio transversal de 1992 adolescentes de 15 a 18 años, reclutados mediante muestreo probabilístico por conglomerados, estratificado y aleatorizado. Las prevalencias de rinitis alérgica y dermatitis atópica se identificaron con el cuestionario propuesto en The Internacional Study of Asthma and Allergies in Childhood.Resultados: Se incluyeron 1056 mujeres (53 %) y 936 hombres (47 %). La prevalencia de rinitis alérgica fue de 9.0 % (IC 95 % = 7.8-10.4); la frecuencia fue mayor en las mujeres (6.7 % versus 11.1 %, p = 0.001). Los síntomas de rinitis más conjuntivitis predominaron en las mujeres (16.0 % versus 23.1 %, p < 0.0001). La prevalencia de dermatitis atópica fue de 5.2 % (IC 95 % = 4.3-6.2); fue más frecuente en las mujeres (7.7 % versus 2.4 %, p < 0.0001). Los principales factores asociados con rinitis alérgica y dermatitis atópica fueron sexo femenino y atopia familiar (p < 0.001).Conclusiones: Se registró diferencia significativa en la prevalencia de rinitis alérgica y dermatitis atópica conforme el sexo en los adolescentes tardíos; las mujeres fueron las más afectadas. La atopia familiar fue otro factor asociado.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.